Treatment of Morbid Obesity: Intensive Lifestyle Intervention vs. Bariatric Surgery

Thomas Bächler¹, Dimitris Papamargaritis², Marco Bueter¹ and Carel W le Roux³*

¹Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zürich, Zürich, Switzerland
²Department of Diabetes and Endocrinology, Leicester Royal Infirmary Hospital, Leicester, UK
³Experimental Pathology, Conway Institute, School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland

Abstract

Obesity has reached an epidemic dimension composing a serious threat to health systems worldwide. It has been associated with numerous comorbidities including cardiovascular disease, type 2 diabetes mellitus, cancer, non-alcoholic fatty liver disease, arthritis, infertility, eating disorders, unemployment and a reduced quality of life. Bariatric surgery is currently the only effective treatment for severe obesity. Non-surgical treatment modalities include lifestyle changes, diet and/or exercise, with pharmacotherapy and less invasive medical devices. This article therefore aims to discuss the available therapy options including surgical and non-surgical treatments as well as to compare both modalities regarding their clinical effectiveness.

Keywords: Obesity; Health problem; Causes of obesity

Introduction

Obesity is an increasingly prevalent worldwide health problem. The prevalence of the disorder in adults has more than tripled in the past decade, and obesity currently affects approximately 20-35% of the general population in the developed world [1]. Obesity is a major contributor to some of the leading causes of death in the developed world, including heart disease, stroke, diabetes and some types of cancer [2]. Specific causes of obesity are still unclear, but it is likely that a combination of metabolic, genetic, psychological, and environmental factors all contribute to the obesity epidemic [3]. Multiple studies have been performed the last years in the area of obesity and have provided a variety of options for treatment of obesity and its related comorbidities. Treatment options can be separated into non-surgical and surgical interventions, i.e., lifestyle, diet and/or exercise, with pharmacotherapy and less invasive medical devices compared to operations such as Roux-en-Y bypass, sleeve gastrectomy and gastric banding.

The aim of this paper will be to discuss the available treatment options and their effect on all the components of morbid obesity as categorised by the King's Obesity Staging score [4,5]. Levels of evidence are given where appropriate according to the Oxford Centre for Evidence-based Medicine Levels of Evidence (www.cebm.net).

Non-Surgical interventions

Airway

In the Look AHEAD study, the patients were randomized to an Intensive Lifestyle Intervention (ILI) or to a Diabetes Support and Education Program (DSE) [6]. Among obese adults with type 2 diabetes and obstructive sleep apnoea, ILI produced greater reductions in weight and apnea-hypopnea index over a 4 year period than the DSE (Evidence level 1b). Beneficial effects of ILI on apnea hypopnea index at 1 year persisted at 4 years, despite an almost 50% weight regain. Effect of ILI on apnea-hypopnea index was largely, but not entirely, due to weight loss. Change in apnea-hypopnea index over time was related to the amount of weight loss while remission of OSA at 4 years was 5 times more common with ILI (20.7%) than DSE (3.6%) [7].

Body mass index (BMI)

During the Look AHEAD study the mean weight loss in the ILI at the end of the first year was 8.6% (Evidence level 1b). This was followed by weight regain through year five and then a subsequent gradual decrease in weight, resulting in an average weight loss of 6.0% after 9.6 years. The DSE (control) group lost a total of 3.5% weight gradually throughout the study [8].

Adding pharmacotherapy to ILI add another 2-3 kg weight loss [9] while medical devices such as the duodenal jejunal bypass can lead to 15-20% weight loss after 1 year [10,11]. However, long-term results after the removal are not yet available.

Cardiovascular disease (CVD)

Patients in the ILI of the Look AHEAD study, lost more weight, improved their cardiovascular fitness, had lower HbA1C, lower systolic and diastolic blood pressure, elevated high-density lipoprotein cholesterol, and lower triglycerides, but despite all the improvements in there was no difference in cardiovascular morbidity and mortality, even in overweight or obese adults with type 2 diabetes [8,12]. The SCOUT study also showed that intentional weight loss with sibutramine lowered body mass index, but did not reduce mortality.

Diabetes

In Look AHEAD, the ILI group was significantly more likely to experience partial or complete remission (11.5% during the first year and 7.3% at year 4, compared with 2.0% for the DSE group at both time points) [13] (Evidence level 1b). Medication such as GLP-1 analogues reduce weight by 3-6% while also increasing postprandial insulin and thus reducing HbA1c by ~1% [14,15]. Regarding the available devices, the duodenal jejunal bypass seems to have an impressive effect on HbA1C with absolute reductions of ~2% [16,17]

Economical

Look AHEAD found that the ILI group reduce the use of

---

*Corresponding author: Carel le Roux, Experimental Pathology Conway Institute, School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland, E-mail: c.leroux@imperial.ac.uk

Received July 01, 2013; Accepted September 26, 2013; Published October 04, 2013


Copyright: © 2013 Bächler T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
medications cost related with cardiovascular risk protection compared to the DSE group from US $173 to $143 per month [18] (Evidence level 1b).

Functional (physical activity)
In Look AHEAD the ILI reduced severe disability and increased good mobility after 4 years [19]. In a subgroup of patients the ILI improved the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) with reduced pain, stiffness, and improved physical function [20] (Evidence level 1b).

Health status perceived
The Beck Depression Inventory (BDI) improved in patients in the ILI in the Look AHEAD study [23] (Evidence level 1b). The 36-Item Short-Form Health Survey Physical Component Summary (PCS) and the Mental Health Component Summary (MCS) scores also improved after ILI [24].

Body image
The ILI group had improvements of the body morph assessment version 2.0 (BMA 2.0) to assess perceived current body size, ideal body size, acceptable body size, and body image dissatisfaction at baseline and 1 year [25] (Evidence level 1b).

Junction of gastro-oesophagus
A recent systematic review identified seven studies that have evaluated the effect of the lifestyle or diet intervention on Gastro-Oesophageal Reflux Disease (GORD) [26]. Two studies used a very low-calorie liquid diet, one a low-calorie diet, one a very low carbohydrate diet and three, lifestyle interventions. Austin et al. showed an improvement in reflux symptoms and a reduction in acid exposure to the oesophagus with a low carbohydrate diet despite that significant weight loss was achieved [27] (Evidence level 3a). On the other hand, other studies found no improvement in reflux symptoms and pHmetry outcomes following dietary and lifestyle interventions [28,29].

Kidney
A multidisciplinary programme combining diet, exercise and orlistat suggests that significant weight loss and improved physical functioning can be achieved in patients who are obese and have chronic kidney disease, increasing the number that became eligible for kidney transplantation [30].

Liver
In the Look Ahead study completed proton magnetic resonance spectroscopy showed reduced hepatic steatosis in an incident NAFLD in the ILI [31] (Evidence level 1b).

Medications
In the look AHEAD study, the medications prescribed to ILI group to treat diabetes, hypertension, and hyperlipidaemia were reduced compared with the DSE group at 1 and 9.6 years after intervention [18,32] (Evidence level 1b).

Surgical Interventions
The most common bariatric procedures are Roux-en-Y gastric bypass (RYGB), Gastric banding (GB) and Sleeve Gastrectomy (SG) [33]. The complications of bariatric surgery are being reduced by good surgical practice in specialist centres and the overall risk of death and other adverse outcomes are low. The Longitudinal Assessment of Bariatric Surgery-1 (LABS-1) study including 4431 bariatric procedures reported a 30-day mortality rate of 0.3%. Main causes of death were pulmonary embolism, cardiac events and anastomotic leakages [34]. The incidence of early perioperative complications after bariatric surgery is 7.3% [35]. Rates of potentially life-threatening complications such as anastomotic leakages, obstruction and hemorrhage are considerably higher among patients undergoing RYGB (3.1%) or SG (2.2%) than after GB (0.8%) [35]. Significant risk factors for surgical complications include a BMI >50 kg/m², male gender, hypertension, age >45 years and a known medical history of thromboembolism [36]. The incidence of venous thromboembolism or medical complications with cardiac, renal or respiratory failure has been reported to be highest in RYGB patients [35]. Late gastrointestinal complications including dumping syndrome with concomitant hypoglycaemia, symptomatic cholelithiasis or gastroesophageal reflux disease and deficiency of micronutrients make long-term follow up of bariatric patients mandatory [37].

Airway
The Apnea- Hypopnea Index (AHI) is improved after surgical induced weight loss, but in most patients moderately to severe OSAS persists [38] (Evidence level 3a). However, 66% of asthmatics undergoing bariatric procedures show a complete resolution after substantial weight loss [39].

Body mass index
The average body weight loss after surgery varies from 15% to 35% depending on the procedure used [33] (Evidence level 2a). Body weight reaches its nadir usually one to two years after bariatric procedures and increases afterwards [40]. The prospective, controlled Swedish Obese Subject (SOS) Study reported that after 10 years body weight reduction was 25% after RYGB and 13% after GB [40]. Randomized controlled trials (RCT) comparing weight loss after RYGB and SG reported heterogeneous results, but differences between the two procedures seem to be minor [41-43].

Cardiovascular disease
The Swedish Obese Subjects (SOS) study demonstrated improvements in T2DM, triglyceride and diastolic blood pressure 10 years after bariatric surgery, but no effect for systolic blood pressure and low density lipoprotein levels [44]. Improvement of the risk profile for cardiovascular disease delays the progression of atherosclerosis by the threefold in patients undergoing bariatric procedures [45]. The non-randomized evidence suggests that obese patients treated by metabolic surgery have mortality benefit when compared to non-surgically treated control group [40] (Evidence level 2a). The lower mortality in the non-randomized surgical group seems to be mainly due to a reduced incidence of cardiovascular deaths and cancer in comparison to the control group [46].

Diabetes (T2DM)
Randomized controlled trials have shown RYGB to be an effective treatment for hyperglycaemia in T2DM [47, 48] (Evidence level 1a). Until recently, there was no definition for the remission of diabetes, but the impressive effects of surgery led the American Diabetes Association (ADA) to create criteria for remission of diabetes [49].
Partial remission is defined as HbA1C levels below 6.5% and fasting glucose levels between 100 and 125 mg/dl (5.6–6.9 mmol/l) for at least 1 year in the absence of any active pharmacologic therapy or ongoing procedures [32]. Complete remission can be diagnosed when HbA1C levels are <6% with a fasting glucose below 100 mg/dl (5.6 mmol/l) for at least 1 year in the absence of any active pharmacologic therapy or ongoing procedures. After RYGB 41–57% of patients have remission of T2DM after 1 year [32,50,51].

**Economic**

Surgery is not more expensive than medical care [52,53]. Recent data indicate that the costs related to a higher number of medical consultations in the first years after bariatric surgery are balanced by the higher drug costs in the non-surgical group during follow up [54]. Health related quality of life after RYGB improves significantly more than nonsurgical care [30,55] (Evidence level 3a).

**Functional**

Severe obesity is major risk factor for osteoarthritis [56] and is associated with musculoskeletal pain [57]. Hence, obesity significantly restricts activities of daily living such as walking and climbing stairs [58]. In contrast, work-restricting pain in the neck, back or knees has been reported to improve or even resolve after bariatric surgery [57]. The amelioration in vitality, physical functioning and body pain (Evidence level 3a) are well reflected by the improvement in the physical components of the short form health survey (SF-36) after bariatric operations [55].

**Gonadal**

Incidence of subfertility (41.9%) and polycystic ovary syndrome (13.1%) among women undergoing bariatric surgery is consistently higher than in the general population [59]. The younger in age, the higher the risk for gonadal dysfunction [59]. There is increasing evidence that bariatric surgery regularizes menstrual cycles and improves fertility in young women [60] (Evidence level 3b).

**Health status perceived**

Severe obesity is associated with multiple forms of negative health impact that affects quality of life. It has been suggested that 25%–30% of patients suffer from marked clinical symptoms of depression before surgery [58]. In the SOS study, health perceptions improved by 11% of patients with a BMI >35 kg/m² and T2DM having RYGB or SG showed that both retinopathy grading and nephropathy markers, including urine Albumin Creatinine Ratio (ACR) improved significantly after surgery [70]. Mingrone et al. showed that not only did markers of kidney damage such as proteinuria improve 10 years after bariatric surgery, but kidney function as measured by glomerulofiltration rate was preserved in comparison to the progressive deterioration in both kidney damage and kidney function in a matched cohort of patients receiving best medical care [71].

**Kidney**

Urine output and sodium excretion increase after RYGB surgery in rats [67] and humans [68] (Evidence level 3a). In addition, RYGB surgery is associated with an improvement in urinary and systemic inflammatory markers in patients [69]. A retrospective analysis in 83 patients with a BMI >35 kg/m² and T2DM having RYGB or SG showed that both retinopathy grading and nephropathy markers, including urine Albumin Creatinine Ratio (ACR) improved significantly after surgery [70].

**Medication**

Obesity and its related diseases are associated with an increased prescriptive drug use when compared to the normal weight population. The number of prescribed drugs decreases from 6.93 before to 4.88 within the 6 months after surgery [72] (Evidence level 3a). However, 44.8% of patients who had no pharmaceutical treatment prior to surgery had at least one prescribed drug 6 years after surgery which was even higher when compared to a conventionally treated control group [73].

**Conclusion**

The clinician's armamentarium against obesity and T2DM is improving through the use of specific dietary modifications, novel medical devices, pharmacotherapy and surgery. Lifestyle interventions combined with pharmacotherapy lead to a long-term weight loss of 5–10%. This weight loss in obese patients with T2DM seems to be inadequate to reduce mortality. On the other hand, weight loss of 5−10% lead to clinically meaningful improvements in glycated haemoglobin levels and better control of diabetes. Other benefits include reductions in deep apnea, depression, number of medication as well as improvements in quality of life, physical and sexual functioning. Bariatric surgery leads to clinically significant and long-term maintained body weight loss and reduction in obesity related morbidity and mortality. Complication rates and surgical mortality have decreased over the last decades. Reducing body weight and improving the manifold comorbidities may improve the economic burden of obesity. It does not appear sensible anymore to subject all patients to intensive lifestyle interventions in the hope to improve mortality. The same level of evidence for surgery is still awaited, but it appears that a more informed patient selection is required for all modalities of treatment. If this can be combined with honest expectation setting then worthwhile long term benefits may be more readily achieved.

**References**

3. Centers for Disease Control and Prevention (CDC) Overweight and Obesity: causes and consequences.


